EUVIMEDEUVIMED entdecken
Crossref

Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus

Robert W Cross iD, Courtney Woolsey iD, Victor C Chu iD, Darius Babusis iD, Roy Bannister iD, Meghan S Vermillion iD, Romas Geleziunas, Kimberly T Barrett iD, Elaine Bunyan iD, Anh-Quan Nguyen iD, Tomas Cihlar, Danielle P Porter iD und 10 weitere

Science · 2024

DOI: 10.1126/science.adk6176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, 2024. Verfasst von Robert W Cross und 21 weiteren Autor:innen. Beteiligte Einrichtung: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA. Hauptthemen laut MEDLINE: Ebolavirus, Hemorrhagic Fever, Ebola, Nucleosides, Alanine. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obeldesivir (ODV, GS-5245) is an orally administered prodrug of the parent nucleoside of remdesivir (RDV) and is presently in phase 3 trials for COVID-19 treatment. In this work, we show that ODV and its circulating parent nucleoside metabolite, GS-441524, have similar in vitro antiviral activity against filoviruses, including Marburg virus, Ebola virus, and Sudan virus (SUDV). We also report that once-daily oral ODV treatment of cynomolgus monkeys for 10 days beginning 24 hours after SUDV exposure confers 100% protection against lethal infection. Transcriptomics data show that ODV treatment delayed the onset of inflammation and correlated with antigen presentation and lymphocyte activation. Our results offer promise for the further development of ODV to control outbreaks of filovirus disease more rapidly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EbolavirusHemorrhagic Fever, EbolaNucleosidesAlanineProdrugsAntiviral AgentsAnimalsAdministration, OralMacaca fascicularisAdenosine MonophosphateAdenosine

Substanzen

NucleosidesAdenosine MonophosphateAlanineProdrugsAntiviral AgentsremdesivirGS-441524Adenosine

Autor:innen und Institutionen

  • Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
  • Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
  • Gilead Sciences, Inc., Foster City, CA, USA.

ORCID-Profile: Robert W Cross, Courtney Woolsey, Victor C Chu, Darius Babusis, Roy Bannister, Meghan S Vermillion, Kimberly T Barrett, Elaine Bunyan, Anh-Quan Nguyen, Danielle P Porter, Abhishek N Prasad, Daniel J Deer, Krystle N Agans, Jasmine Martinez, Mack B Harrison, Natalie S Dobias, Karla A Fenton, John P Bilello, Thomas W Geisbert

Förderung

  • NIAID NIH HHS

Zitieren

APA

Cross, R. W., Woolsey, C., Chu, V. C., Babusis, D., Bannister, R., Vermillion, M. S., Geleziunas, R., Barrett, K. T., Bunyan, E., Nguyen, A. Q., Cihlar, T., Porter, D. P., Prasad, A. N., Deer, D. J., Borisevich, V., Agans, K. N., Martinez, J., Harrison, M. B., Dobias, N. S., …, & Geisbert, T. W. (2024). Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus. Science. https://doi.org/10.1126/science.adk6176

Vancouver

Cross RW, Woolsey C, Chu VC, Babusis D, Bannister R, Vermillion MS, et al. Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus. Science. 2024. doi:10.1126/science.adk6176

BibTeX
@article{Cross2024,
  author = {Cross, Robert W and Woolsey, Courtney and Chu, Victor C and Babusis, Darius and Bannister, Roy and Vermillion, Meghan S and Geleziunas, Romas and Barrett, Kimberly T and Bunyan, Elaine and Nguyen, Anh-Quan and Cihlar, Tomas and Porter, Danielle P and Prasad, Abhishek N and Deer, Daniel J and Borisevich, Viktoriya and Agans, Krystle N and Martinez, Jasmine and Harrison, Mack B and Dobias, Natalie S and Fenton, Karla A and Bilello, John P and Geisbert, Thomas W},
  title = {Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus},
  journal = {Science},
  year = {2024},
  doi = {10.1126/science.adk6176}
}
Kostenlos starten →